ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0419

Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study

Gregory McDermott1, Xiaoqing Fu2, Claire Cook3, John Stone4, Yuqing Zhang5 and Zachary Wallace6, 1Brigham and Women's Hospital, Brookline, MA, 2Massachusetts General Hospital, Boston, MA, 3Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 5Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Harvard Medical School, Boston, MA, 6Massachusetts General Hospital, Newton, MA

Meeting: ACR Convergence 2021

Keywords: ANCA associated vasculitis, Mortality, Renal

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Vasculitis – ANCA-Associated Poster (0414–0436)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is associated with increased risk of end-stage renal disease (ESRD) and death. In most cases, circulating ANCA targeting proteinase-3 (PR3) or myeloperoxidase (MPO) are present and may be pathogenic. Studies of the association of post-treatment ANCA titers with future outcomes have yielded conflicting results. We evaluated the association of achieving a negative ANCA titer during the first year of treatment with ESRD and death.

Methods: Cases were obtained from a consecutive inception cohort of AAV patients who received care at a large multi-hospital system between 2002-2019. All cases were PR3- or MPO-ANCA+. ANCA titers were obtained from a single reference laboratory. Mortality data were obtained from the National Death Index and ESRD status from the United States Renal Data System. To address confounding and immortal-time bias, we performed a target trial emulation study to examine the association of post-induction ANCA titer with risk of ESRD or death using a previously described cloning, censoring and weighting approach. We designed a hypothetical trial with two management strategies: “achieve a negative titer” or “do not achieve negative titer” within 365 days of induction. “Clones” of each patient were included in each hypothetical management arm and censored when they violated the assigned strategy. The composite outcome – risk of ESRD or death within five years – was estimated using Cox models after accounting for informative censoring using inverse-probability-of-censoring weighting and adjusting for baseline covariates.

Results: The study included 589 patients (mean age: 60 years; 58% female; 88% white) with 24.4 + 24.6 months of mean follow up (Table 1). The majority were MPO-ANCA+ (70%) and had renal manifestations (65%). Rituximab (RTX)-based induction strategies were used in 48%. 32% achieved a negative titer within one year of induction. In the target trial, the HR for the primary outcome of ESRD or death was 1.02 (95%CI 0.84-1.24) in the group that achieved a negative titer compared to the group that did not (Table 2). In analyses stratified by remission induction strategy, the HR for ESRD or death was 0.95 (95%CI 0.72-1.26) in RTX-based and 1.11 (95%CI 0.83-1.48) in cyclophosphamide (CYC)-based regimen users when comparing those who achieved a negative titer vs those who did not. The HR for ESRD or death was 0.85 (95%CI 0.56-1.27) in the PR3-ANCA+ and 1.12 (95%CI 0.90-1.40) in the MPO-ANCA+ groups that achieved a negative titer. There was a trend toward lower risk of death among PR3-ANCA+ patients who achieved a negative titer (HR 0.58 [95%CI 0.33-1.02]).

Conclusion: In this target trial using a large cohort of AAV patients, achieving a negative ANCA titer within one year of induction was not associated with improved renal or mortality outcomes. This finding was seen in both RTX- and CYC-treated patients. There was a trend towards decreased risk of death in the PR3-ANCA+ patients who achieved a negative titer, although this did not reach statistical significance. These findings suggest that post-induction ANCA titers have limited ability to predict mortality and ESRD outcomes in AAV.


Disclosures: G. McDermott, None; X. Fu, None; C. Cook, None; J. Stone, Principia Biopharma Inc, a Sanofi Company, 5, 12, personal fees; Y. Zhang, None; Z. Wallace, Bristol-Myers Squibb, 5, Principia/Sanofi, 5, Viela Bio, 2, MedPace, 2.

To cite this abstract in AMA style:

McDermott G, Fu X, Cook C, Stone J, Zhang Y, Wallace Z. Post-induction ANCA Titer Does Not Predict Mortality or Renal Outcomes: A Target Trial Emulation Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/post-induction-anca-titer-does-not-predict-mortality-or-renal-outcomes-a-target-trial-emulation-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-induction-anca-titer-does-not-predict-mortality-or-renal-outcomes-a-target-trial-emulation-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology